

INDICATION: DUPIXENT is indicated for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE).



Please join us for an expert-led discussion on:

Transform the Way You Manage Eosinophilic Esophagitis (EoE) - The First and Only FDA-Approved Treatment for EoE Patients As Young As 1 Year

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION: DUPIXENT is contraindicated in patients with known hypersensitivity to dupilumab or any of its excipients.

Please see additional Important Safety Information on reverse side and accompanying full [Prescribing Information](#).

YOU'RE INVITED

October 16, 2025
6:30 PM Central
(Please arrive 30 minutes prior to start of the presentation.)

Ember Kitchen
314 Belanger Street
Houma, Louisiana 70360

PRESENTED BY

Lemuel Jenkins, MD
GastroGroup

HOSTED BY

Spencer Neff
spencer.neff@sanofi.com
504-606-6996
SAN0017827

You may RSVP to your program host.



Please join us for an expert-led discussion on:

Transform the Way You Manage Eosinophilic Esophagitis (EoE) - The First and Only FDA-Approved Treatment for EoE Patients As Young As 1 Year

IMPORTANT SAFETY INFORMATION, CONTINUED

WARNINGS AND PRECAUTIONS

Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions, angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT.

Risk Associated with Abrupt Reduction of Corticosteroid Dosage: Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a healthcare provider. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with Co-morbid Asthma: Advise patients with co-morbid asthma not to adjust or stop their asthma treatments without consultation with their physicians.

Arthralgia and Psoriatic Arthritis: Arthralgia has been reported with the use of DUPIXENT with some patients reporting gait disturbances or decreased mobility associated with joint symptoms; some cases resulted in hospitalization. Cases of new-onset psoriatic arthritis requiring systemic treatment have been reported with the use of DUPIXENT. Advise patients to report new-onset or worsening joint symptoms. If symptoms persist or worsen, consider rheumatological evaluation and/or discontinuation of DUPIXENT.

Parasitic (Helminth) Infections: It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until the infection resolves.

Vaccinations: Consider completing all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating DUPIXENT. Avoid use of live vaccines during treatment with DUPIXENT.

ADVERSE REACTIONS: The most common adverse reactions (incidence $\geq 2\%$) in patients with EoE are injection site reactions, upper respiratory tract infections, arthralgia, and herpes viral infections.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** A pregnancy exposure registry monitors pregnancy outcomes in women exposed to DUPIXENT during pregnancy. To enroll or obtain information call 1-877-311-8972 or go to <https://mothertobaby.org/ongoing-study/dupixent/>. Available data from case reports and case series with DUPIXENT use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus.
- **Lactation:** There are no data on the presence of DUPIXENT in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

Please see accompanying full **Prescribing Information**

Meals may not be provided to certain persons at this speaker program. By accepting a meal at this program, you represent that none of these descriptions apply to you: (1) Minnesota licensed healthcare provider; (2) New Jersey prescriber (for in office programs); (3) Vermont licensed healthcare provider; (4) anyone prohibited from accepting things of value, such as the food or drink at this event, by other state or federal laws, or by her or his employer's policies. Thank you for your understanding. In accordance with the PhRMA Code on Interactions with Healthcare Professionals, attendance at this program is limited to healthcare professionals. Accordingly, attendance by guests or spouses is not permitted. No CME credits are available.

sanofi | **REGENERON**®

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.
DUPIXENT® is a registered trademark of Sanofi Biotechnology.
04/2025 US.DUP.25.04.0087

DUPIXENT®
(dupilumab) Injection
200mg • 300mg